Company: CERO
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-044335
Chunk: 3

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 1
Chunk 3
---
616  
     141,125  
     5,845 

See accompanying notes to the condensed consolidated financial statements

Reflects a 1-for-100 reverse stock split effective
January 8, 2025

2

CERO THERAPEUTICS HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT

(Unaudited)

    Convertible
    Preferred Stock  
    Series
    A Common  
    Additional  
    Stock  
       
    Total 

    Series
    A  
    Series
    B  
    Series
    C  
    Stock  
    Paid-in  
    Subscriptions  
    Accumulated  
    Stockholders’ 

    Shares  
    Amount  
    Shares  
    Amount  
    Shares  
    Amount  
    Shares  
    Amount  
    Capital  
    Receivable  
    Deficit  
    Deficit 
  
    Balance
    at December 31, 2024 (Successor) 
     1,894  
    $1,708,396  
     273  
    $218,051  
     2,853  
    $1,249,999  
     2,415,883  
    $242  
    $67,142,046  
    $(1,295,444) 
    $(70,917,853) 
    $(1,894,563)
  
    Issuance
    of shares of Series A Preferred Stock upon exercise of Series A Preferred Warrants 
     625  
     500,000  
     -  
     -  
     -  
     -  
     -  
     -  
     (500,000) 
     500,000  
     -  
     500,000 
  
    Sale
    of common stock 
     -  
     -  
     -  
     -  
     -  
     -  
     300,000  
     30  
     587,970  
     -  
     -  
     588,000 
  
    Sale of pre-funded warrants, net of issuance costs of $839,004